Literature DB >> 24674830

Type II endometrial cancer in Hispanic women: tumor characteristics, treatment and survival compared to non-Hispanic white women.

Haider Mahdi1, Huiying Hou2, Li-Lian Kowk3, Mehdi Moslemi-Kebria2, Chad Michener2.   

Abstract

OBJECTIVES: To compare survival of Hispanic white (HW) and non-Hispanic white (NHW) women with type II endometrial adenocarcinoma (EC).
METHODS: Patients with serous, clear cell or grade 3 endometrioid EC were identified from the Surveillance, Epidemiology, and End Results (SEER) program 1988-2009 and were divided into HW and NHW. HW were subdivided into natives and immigrants.
RESULTS: Of the 14,434 women, 13,012 (90.2%) were NHW and 1422 (9.8%) were HW. HW were younger than NHW (mean 63 vs. 68years, p<0.001). A higher proportion of HW presented with late stage disease than NHW (43.8% vs. 36.6%, p=0.04). Performing lymphadenectomy was not different but HW were more likely to have positive lymph nodes than NHW (27.6% vs. 23.1%, p=0.02). Further, HW were less likely to receive radiation than NHW (39.5% vs. 42.3%, p=0.04). No difference in clinicopathologic characteristics was found between immigrant and native HW. In multivariate models adjusting for age, stage, histology, surgical treatment, extent of lymphadenectomy, and radiation therapy, no difference in overall survival (OS) (HR 1.06, 95% CI 0.97-1.16, p=0.19) and cancer-specific survival (CSS) (HR 1.02, 95% CI 0.91-1.14, p=0.75) was found between HW and NHW. Interestingly, immigrant HW had better OS (HR 0.74, 95% CI 0.62-0.89, p<0.001) and CSS (HR 0.72, 95% CI 0.58-0.90, P=0.003) than native HW.
CONCLUSIONS: Although they were more likely to present with advanced stage and positive nodal disease, no difference in outcome was noted between Hispanic and non-Hispanic whites with EC. Interestingly, immigrant HW had more favorable outcome compared to native HW.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hispanic whites; Non-Hispanic whites; Place of birth; Racial disparity; Survival; Type II endometrial cancer

Mesh:

Year:  2014        PMID: 24674830     DOI: 10.1016/j.ygyno.2014.03.562

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype.

Authors:  Megan A Clarke; Susan S Devesa; Anne Hammer; Nicolas Wentzensen
Journal:  JAMA Oncol       Date:  2022-06-01       Impact factor: 33.006

2.  Lack of improvement in survival rates for women under 50 with endometrial cancer, 2000-2011.

Authors:  Ana M Rodriguez; Kathleen M Schmeler; Yong-Fang Kuo
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-15       Impact factor: 4.553

3.  Guideline-concordant treatment is associated with improved survival among women with non-endometrioid endometrial cancer.

Authors:  Jhalak Dholakia; Elyse Llamocca; Allison Quick; Ritu Salani; Ashley S Felix
Journal:  Gynecol Oncol       Date:  2020-03-23       Impact factor: 5.482

4.  Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only.

Authors:  Linda Hertlein; Johanna Rath; Christine Zeder-Göss; Sophie Fürst; Daniela Bayer; Fabian Trillsch; Sven Mahner; Alexander Burges; Udo Jeschke
Journal:  Oncol Lett       Date:  2017-07-18       Impact factor: 2.967

5.  Racial disparities in outcomes for high-grade uterine cancer: A California cancer registry study.

Authors:  Mana Baskovic; Daphne Y Lichtensztajn; Trung Nguyen; Amer Karam; Diana P English
Journal:  Cancer Med       Date:  2018-08-19       Impact factor: 4.452

6.  Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers.

Authors:  Megan A Clarke; Susan S Devesa; Summer V Harvey; Nicolas Wentzensen
Journal:  J Clin Oncol       Date:  2019-05-22       Impact factor: 44.544

7.  The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States-part 3: Hispanic-American patients.

Authors:  Shearwood McClelland; Carmen A Perez
Journal:  Adv Radiat Oncol       Date:  2017-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.